Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

UConn proposes new hires re research & startups

Top UConn leaders want to spend $46 million to hire ten new research, innovation and entrepreneurship faculty and provide them new lab space and equipment, as...

| By Kelley Gipson

Connecticut Innovations invests $15.1M in 4Q 2021

Quasi-public venture capital firm Connecticut Innovations invested $15.1 million in 47 deals during the last quarter of 2021, the New Haven-based company reports. Of that sum,...

| By Kelley Gipson

Weekly Roundup – March 24, 2022

View this email in your browser Weekly Roundup – March 24, 2022  Shipman and Goodwin started a podcast! From Lawyer to Employer: A Shipman Podcast brings you the latest...

| By Kelley Gipson

Bactana in pet care agreement with ArcaNatura

Bactana has signed a distribution agreement with France-based ArcaNatura SAS to launch Bactana’s first commercial product, Pawsni™ Glucose Control. FPZ-100, Bactana’s patent pending active ingredient...

| By Kelley Gipson

BioCT welcomes JLL as a Supporter Sponsor

JLL is a Fortune 500, leading professional services firm that specializes in commercial real estate in the Life Science sector. Whether your organization is mature,...

| By Kelley Gipson

Invea Therapeutics announces poster presentations

Invea Therapeutics reports that an abstract entitled, “Using An Artificial Intelligence and Machine Learning Platform to Identify Mast Cell-Focused Therapeutic Targets for Gut-Brain Axis Disorders,” has...

| By Kelley Gipson

Sema4 Named to list of innovative companies

Sema4 has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2022. “It is an honor that Fast Company has named...

| By Kelley Gipson

BioCT welcomes new member Deloitte

Life sciences companies continue to respond to a changing global landscape, and strive to pursue innovative solutions to address today’s challenges. The Deloitte Life Sciences practice understands...

| By Kelley Gipson

Weekly Roundup – March 16, 2022

View this email in your browser Weekly Roundup – March 16, 2022  Boehringer Ingelheim is off to a strong start in ’22 with continued positive...

| By Kelley Gipson

Trial of BI Jardiance® shows positive efficacy

A trial evaluating the effect of Boehringer-Ingelheim’s Jardiance® (empagliflozin) in adults with chronic kidney disease will stop early following an assessment of positive efficacy. “We are...